Research Signal – Source date 2024-12-27
Many postmenopausal women describe moments of distraction, forgetfulness or difficulty concentrating. A ClinicalTrials.gov entry asks whether a dietary supplement called Cortexium can improve cognitive performance in this setting. The question is worth separating from the marketing language that often surrounds supplements: what would a controlled six-week comparison actually establish?
The registry entry represented here is dated December 27, 2024. It identifies the aim as testing whether Cortexium improves cognitive function in postmenopausal women. The current record later describes the study’s design and lifecycle, but it does not provide a result showing that the supplement helped memory or concentration.
A formula tested as a whole
The study is described as a randomized, parallel-group intervention. Participants were assigned to receive either Cortexium or a matching placebo supplement every day for six weeks. The current record reports actual enrollment of 70 participants.
The treatment is described as containing pyrroloquinoline quinone, or PQQ, gamma-aminobutyric acid, or GABA, and B vitamins. The title and background also mention caffeine, while the supplied arm and intervention descriptions name PQQ, GABA and B vitamins without naming caffeine. The discrepancy is not resolved by the evidence provided here, so it should not be silently filled in.
The comparison tests the Cortexium formulation as a combined product. Even if the treatment group performed differently from the placebo group, that result would not isolate the contribution of PQQ, GABA, caffeine or any individual B vitamin. The registry background presents proposed biological roles for the ingredients, such as antioxidant activity, neurotransmitter support or stimulation, but those explanations are the rationale for the trial rather than findings from it.
What the six-week tests measure
The primary outcome is the Neurocognition Index, or NCI, calculated from computerized testing using the Central Nervous System-Vital Signs, known as CNS-VS. In plain language, the NCI is intended to provide an overall cognitive score rather than a single memory test.
The secondary outcome uses 11 items from the CNS-VS cognitive-function domain. These cover composite memory, verbal and visual memory, psychomotor speed, reaction time, complex attention, cognitive flexibility, processing speed, executive function, simple attention and motor speed. The broader set matters because cognition is not one ability. A group difference in an overall index would answer a different question from a difference concentrated in memory, attention or reaction time.
The six-week interval also gives the trial a specific scope. It can examine performance at the end of the treatment period in relation to the planned cognitive measures. It does not turn a computerized score into a direct measure of everyday independence, work performance or long-term brain health. Those outcomes would require evidence beyond the endpoints listed in the registry description.
Completion tells us where the study stopped, not what it found
The current record lists the study as completed, with an actual start date of May 20, 2025 and actual primary and overall completion on June 5, 2026. These dates are later administrative details from the current record’s lifecycle. They should not be read back as though they were part of the December 2024 registry entry or as though they supplied its original wording.
The registry snapshot supplied for this article says that results have not been posted. That means this record cannot establish the direction or size of any cognitive effect, whether an observed difference was statistically persuasive, or how well the supplement was tolerated. Completion indicates that the planned study period reached its recorded endpoint; it is not an efficacy result.
The important limits of the comparison
Even a positive result on the listed tests would need careful interpretation. A six-week cognitive assessment would not establish a durable benefit, prevention of dementia or modification of neurodegeneration. Nor would a study described as involving healthy postmenopausal women automatically answer whether the supplement helps everyone experiencing memory difficulties.
The supplied eligibility summary identifies female participants aged 18 or older, but it does not provide the participants’ age distribution or the full eligibility criteria. The material also does not resolve ingredient doses, the caffeine-description discrepancy or the masking arrangements. Those are limits of the information available here, not evidence that the study omitted those details.
The same caution applies to the registry’s background statements about how common menopause-related cognitive complaints are and what the ingredients might do biologically. They explain why the investigators posed the question. They are not measurements from this randomized comparison.
What this could mean for memory support after menopause
If the completed trial produces a reproducible cognitive benefit that is meaningful beyond computerized scores and is accompanied by acceptable safety evidence, it could support a more evidence-based supplement option for postmenopausal women seeking help with memory or concentration. That would give clinicians and patients a clearer basis for discussing a combined formulation than ingredient theories alone.
The prospect remains conditional because the available registry record does not yet show the trial’s results. Study completion records that the investigation reached its scheduled endpoint; it does not deliver a proven benefit. The useful promise of this research is the possibility of clarifying whether a specific supplement can make a meaningful difference for the people it was designed to study.
Key Sources
- Primary source: Cognitive Effects of a Dietary Supplement With PQQ, GABA, Caffeine, and B-Vitamins in Healthy Postmenopausal Women: A Randomized Controlled Trial
Government or Regulator · Clinical Trial · 2024-12-27
Keep exploring